It's been a disappointing 2021 so far for the CSL (ASX:CSL) share price

The ASX's former darling has had a difficult year.

| More on:
Medical asx share price fall represented by worried looking patient awaiting vaccine injection

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has continued its disappointing run over recent weeks, falling from a June high of $307.57. While no news has been released by the global biotech, investors may have been growing impatient with the company's performance.

During yesterday's market close, CSL shares finished the day down 0.72% to $279.14. This means that the company's share price has plummeted 10% in the space of 3 weeks.

What's happened in 2021?

It's been a turbulent year for the CSL share price marred primarily by the company's reduced plasma collections during the pandemic.

CSL stated in its half year results that lockdowns, social distancing as well as federal government stimulus payments have had a negative impact on donations. This is particularly bad news for the company as it relies on the plasma from blood donors to make life-saving medicines.

Plasma collection costs rose as CSL was forced to offer bigger cash incentives to donors in the United States. Furthermore, new hygiene measures put in place due to COVID-19 also added to the increased overall cost.

While current plasma levels are expected to eventually bounce back, no one knows exactly when. This uncertain environment appears to have weighed down on investor hope, sending the CSL share price in circles over the past 18 months.

Top brokers weigh in on CSL

As reported by my Fool colleague yesterday, several top brokers have mixed feelings about CSL.

Citi and Goldman Sachs share a neutral rating on the biotech giant, citing price targets of $310 and $305, respectively.

Meanwhile, UBS has a buy rating and $330 price target, representing a potential 18.3% upside to the current share price.

More on the CSL share price

Since hitting a 52-week low of $242 in March this year, CSL shares have rebounded strongly, only to fall again. Interestingly, the company's share price is at the same level the day it released its half-year results for FY21.

On valuation grounds, CSL is the third-largest company listed on the ASX, with a market capitalisation of $127 billion. That puts it just behind Commonwealth Bank of Australia (ASX: CBA) and BHP Group Ltd (ASX: BHP).

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »